FDA Drug recall D-1182-2018
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 2 grain (120 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmace…
- FDA Drug
- Class I
- terminated
- Published 2018-08-29
On 2018-08-29 the FDA classified a Class I recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP), 2 grain (120 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmace… by Westminster Pharmaceuticals, citing failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufactu….
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1182-2018 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2018-08-03 |
| Published | 2018-08-29 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Westminster Pharmaceuticals |
| Distribution | US |
Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 2 grain (120 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-158-04.
Reason
Failed Content Uniformity Specifications: Product was manufactured using an adulterated active pharmaceutical ingredient; additionally, lack of process controls and good manufacturing practices resulted in finished product failing content uniformity specifications which can result in a product having a strength that is more or less than is labeled.
Identifiers
| code_info | Lot #: 15817VP-01, 15817VP-02, 15817VP-03, Exp 9/30/2019; 15818001, Exp 3/31/2020. |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1182-2018%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.